Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acarbose/orlistat - Empros Pharma

Next Previous
Drug Profile

Acarbose/orlistat - Empros Pharma

Alternative Names: EMP-16-01; EMP-16-02

Latest Information Update: 03 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Empros Pharma
  • Class Anorectics; Antihyperlipidaemics; Carbohydrates; Lactones; Obesity therapies
  • Mechanism of Action Alpha-glucosidase inhibitors; Amylase inhibitors; Lipase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Obesity

Most Recent Events

  • 20 May 2025 Empros Pharma plans the phase II POEM trial for Obesity, in May 2025 (NCT06993428) (EudraCT2024-520122-11-00)
  • 21 Nov 2023 Empros Pharma completes a phase II trial for Obesity in Sweden (PO) (EudraCT2022-003320-40) (NCT05934110)
  • 22 Sep 2023 Empros Pharmaceuticals initiates phase I trial for Obesity (In Volunteers) in Sweden (PO) (NCT06013163) (EudraCT2023-505671-74-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top